07:16 AM EDT, 08/28/2024 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday that it has completed dosing in the third cohort of its phase 1/2 clinical trial of OCU410ST, a modifier gene therapy candidate being developed for Stargardt disease.
Three subjects received a single subretinal injection of the highest dose being tested, the company said.
Price: 1.3800, Change: +0.05, Percent Change: +3.76